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Focal segmental glomerulosclerosis (FSGS) is a common pattern of renal injury, seen as both a primary disorder and as
a consequence of underlying insults such as diabetes, HIV infection, and hypertension. Point mutations in the
a-actinin-4 gene ACTN4 cause an autosomal dominant form of human FSGS. We characterized the biological effect of
these mutations by biochemical assays, cell-based studies, and the development of a new mouse model. We found that
a fraction of the mutant protein forms large aggregates with a high sedimentation coefficient. Localization of mutant
a-actinin-4 in transfected and injected cells, as well as in situ glomeruli, showed aggregates of the mutant protein.
Video microscopy showed the mutant a-actinin-4 to be markedly less dynamic than the wild-type protein. We
developed a ‘‘knockin’’ mouse model by replacing Actn4 with a copy of the gene bearing an FSGS-associated point
mutation. We used cells from these mice to show increased degradation of mutant a-actinin-4, mediated, at least in
part, by the ubiquitin–proteasome pathway. We correlate these findings with studies of a-actinin-4 expression in
human samples. ‘‘Knockin’’ mice with a disease-associated Actn4 mutation develop a phenotype similar to that
observed in humans. Comparison of the phenotype in wild-type, heterozygous, and homozygous Actn4 ‘‘knockin’’ and
‘‘knockout’’ mice, together with our in vitro data, suggests that the phenotypes in mice and humans involve both gain-
of-function and loss-of-function mechanisms.
Introduction
In humans, ACTN4 mutations cause a form of focal
segmental glomerulosclerosis (FSGS) (Kaplan et al. 2000).
This lesion, which describes a pattern of injury characterized
by regions of sclerosis in some renal glomeruli, is a common
ﬁnding in kidney disease from a wide range of primary
disorders, including HIV infection, diabetes, and hyper-
tension (Ichikawa and Fogo 1996; Somlo and Mundel 2000).
The four a-actinin genes encode highly homologous
proteins that normally form approximately 100 kDa head-
to-tail homodimers. While the best-deﬁned function of a-
actinin-4 is to cross-link and bundle actin ﬁlaments, a-
actinins have been found to interact with a large and diverse
set of other proteins (Honda et al. 1998; Takada and Beggs
2002). a-Actinin-2 and a-actinin-3 are located predominantly
in the sarcomere, while a-actinin-1 and a-actinin-4 are widely
expressed. In the human kidney, only a-actinin-4 expression
is detected (Kaplan et al. 2000).
Human ACTN4-associated FSGS is inherited in an autoso-
mal dominant pattern. By contrast, mice homozoygous for
Actn4 null alleles have glomerular disease, while heterozygous
Actn4 null mice have no readily apparent phenotype (Kos et
al. 2003). Transgenic mice harboring a mutant Actn4 targeted
to the glomerular podocyte have an FSGS-like lesion,
although it is not clear whether this is due to the dominant
effect of the mutant Actn4 per se or to dysregulated Actn4
expression in this cell (Michaud et al. 2003).
We previously showed that FSGS-associated ACTN4 muta-
tions increase the binding of a-actinin-4 to F-actin (Kaplan et
al. 2000). This was conﬁrmed independently by different
methodology (Michaud et al. 2003). However, the relationship
between altered actin binding and disease is unclear. Of
particular interest is whether the human disease is due to a
gain-of-function effect of mutations on protein function or
due to a partial loss of normal function. We therefore
performed a series of experiments to help us understand the
biological consequences of mutations in ACTN4. We demon-
strate here that mutant a-actinins exhibit altered structural
characteristics, localize abnormally, and have signiﬁcantly
diminished half-life. By developing a mouse model harboring
a disease-associated point mutation, we conﬁrm the patho-
logic effect of this mutation on glomerular function. Our
results suggest that the major effects of Actn4 mutations are
protein misfolding and accelerated degradation, leading to
loss of normal a-actinin-4 function, a-actinin-4 aggregation,
and progressive kidney disease.
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Mutant a-Actinin-4 Conformation
In overlay assays (performed as per Chan et al. 1998; data
not shown), mutant a-actinin-4 is able to bind both mutant
and wild-type a-actinin-4. Since mutant a-actinin-4 polypep-
tides are able to interact, we used sucrose gradient assays to
examine whether the mutant a-actinin-4 dimerizes normally.
We produced radiolabeled in vitro translated wild-type and
mutant a-actinin-4 (K228E, T232I, R235P) and subjected these
proteins to centrifugation in 5%–20% sucrose gradients. We
found that all of the wild-type a-actinin-4 eluted as a single
peak, as expected. By contrast, approximately 80% mutant
a-actinin-4 eluted at the same peak as in wild-type, while
about 20% of the mutant protein eluted much more quickly
and peaked in the ﬁrst fraction. We then used a 10%–40%
sucrose gradient in an attempt to better characterize this
small peak. Again, in multiple experiments, about 20% of the
mutant a-actinins eluted in the ﬁrst fractions. a-Actinin has a
sedimentation coefﬁcient of 6.4 (Feramisco and Burridge
1980), and both wild-type and the majority (approximately
80%) of mutant actinins migrated in this position. However, a
signiﬁcant fraction of mutant a-actinin-4 had a sedimentation
coefﬁcient equal to or greater than 11.3, the sedimentation
coefﬁcient of catalase (Figure 1). This extremely high
sedimentation rate suggests either the presence of large
a-actinin-4 multimers or the existence of large (and perhaps
insoluble) aggregates. When these experiments were per-
formed in the presence of a large excess of cold a-actinin, this
rapidly sedimenting fraction of mutant a-actinin was un-
changed, showing that the abnormally conformed mutant
a-actinin-4 could not be shifted back into normally sediment-
ing mutant/wild-type heterodimers (Figure 1).
a-Actinin-4 Behavior in Cells
We performed both transfection and nuclear injection
studies in a conditionally immortalized podocyte cell line to
look at the effect of disease-associated mutations on
a-actinin-4 localization. Irrespective of the method used to
express the mutant a-actinins in cells, we found altered
localization of the mutants. Consistent with the altered
sedimentation observed in vitro, mutant a-actinin-4 formed
localized aggregates when expressed in cells. We used video
microscopy to view the fate of the green ﬂuorescent protein
(GFP)–a-actinin-4 after nuclear injection of the cDNA.
Similar results were observed in three independent sets of
experiments. In each experiment, 15–35 cells were micro-
injected in the nucleus with plasmid DNA; of these, ﬁve to ten
cells showed signal at 4–6 h after injection. Consistently, the
mutants behaved abnormally, were unevenly distributed in
the cell cytoplasm, and were much less dynamic compared
with the wild-type proteins (Figure 2A; see also Videos S1–S3).
These ﬁndings were consistent with the indirect immuno-
ﬂuorescence (IF) studies performed in Actn4
K228/K228 mice (see
below).
We transfected conditionally immortalized podocytes
derived from Actn4
þ/þ, Actn4
K228E/þ, and Actn4
K228E/K228E mice
with either wild-type GFP–a-actinin-4 or K228E mutant GFP–
a-actinin-4 (Figure 2B). The wild-type GFP–a-actinin-4
showed diffuse cytoplasmic localization in podocytes of all
three genotypes. By contrast, mutant a-actinin-4 showed a
similar aggregated appearance in all three cell types. This
suggests the absence of a strong dominant effect of the
mutant protein on the wild-type, as the endogenous K228E
actinin does not alter the localization of the wild-type GFP-
tagged protein.
We developed a-actinin-4 ‘‘knockin’’ mice using the
methods of homologous recombination in embryonic stem
cells. Previously we developed an Actn4 ‘‘knockout’’ mouse
(Kos et al. 2003). As indicated schematically in Figure 3A,
m a t i n gt h e s em i c ew i t hg e r m l i n eCre transgenic mice
produced offspring in which an intronic loxP-ﬂanked neo-
mycin resistance cassette had been excised. We bred these
heterozygous mice (Actn4
K228E/þ) to generate litters with wild-
type, heterozygous, and Actn4
K228E/K228E mice. We genotyped
mice by testing for the presence or absence of an engineered
silent EarI site as described previously (Kos et al. 2003). The
homozygous K228E mice, in contrast to the Actn4-deﬁcient
model, demonstrated normal levels of Actn4 mRNA expres-
sion (Figure 3B). RT-PCR and sequencing of the transcript
conﬁrmed that the K228E allele was in fact expressed in the
homozoygous mice. However, in multiple tissues tested
(kidney, lung, leukocytes, brain), as well as in ﬁbroblasts
derived from these mice, a-actinin-4 protein expression was
markedly reduced, with an approximately 90% reduction in
protein expression in Actn4
K228E/K228E homozygotes and an
approximately 50% reduction in Actn4
K228E/þ heterozygotes
(Figure 3D). Lymphocytes from a human subject heterozygous
for one ACTN4 K2228E mutation similarly had an approx-
imately 50% reduction in the amount of a-actinin-4
compared with related and unrelated controls (Figure 3E).
a-Actinin-4 Degradation
We observed decreased mutant a-actinin expression in an
immortalized knockin mouse ﬁbroblast homozygous for the
Actn4 K228E mutation, compared with the wild-type ﬁbro-
blast (Figure 3D). To help determine the fate of the mutant
Figure 1. Mutant a-Actinin-4 Sediments Abnormally
(A) Pattern of sedimentation of a-actinin-4 in a 10%–40% sucrose
gradient. Results shown are for wild-type a-actinin-4, K228E a-
actinin-4, and K228E a-actinin-4 after addition of excess cold (wild-
type) a-actinin. A fraction of the mutant a-actinin-4 sedimented at
least as quickly than the highest molecular weight marker, catalase,
which has a sedimentation coefﬁcient of 11.3. This was observed with
all of the other mutants tested as well (data not shown), but never with
labeled wild-type a-actinin-4. Addition of cold a-actinin did not alter
the sedimentation pattern seen with the mutant form of a-actinin-4.
(B) Results illustrated graphically. Units are arbitrary.
DOI: 10.1371/journal.pbio.0020167.g001
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a-Actinin-4 Mutations in Kidney Diseasea-actinin, we performed pulse and pulse–chase studies. We
labeled Actn4
K228E/K228E ﬁbroblasts, Actn4
K228E/þ ﬁbroblasts,
and wild-type ﬁbroblasts with [
35S]methionine for different
timepoints (pulse) following incubation in methionine-
deﬁcient medium. In order to trace the newly synthesized
35S-labeled a-actinins, we used an a-actinin-4-speciﬁc anti-
body to immunoprecipitate a-actinin-4 from the cell lysates.
(We detected no a-actinin-4 in the cell pellets.) As shown in
Figure 4A, we found that at any timepoint, there was less
mutant than wild-type a-actinin-4 synthesized. However, as
shown in Figure 4B, the rates of increase in labeled
a-actinin-4 were similar, suggesting that the low expression
level of mutant a-actinin-4 is not due to a defect in synthesis.
We then labeled the mutant and wild-type ﬁbroblasts with
[
35S]methionine for 3 hours (pulse), following incubation in
methionine-deﬁcient media, and then incubated the cells in
media containing excess cold methionine (chase) for differ-
ent timepoints to follow the degradation of the newly
synthesized a-actinin-4. As shown in Figure 4C and 4D,
mutant a-actinin-4 degraded at a much faster rate than did
the wild-type protein. The estimated half-life of mutant
a-actinin-4 is about 15 h, while the half-life of the wild-type
a-actinin-4 is much greater than 30 h. Three replicate
experiments gave the same results. The rapid degradation
of the K228E mutant a-actinin-4 is reversed by treatment
with lactacystin (Figure 4E), indicating that this mutant form
of a-actinin-4 is degraded through the ubiquitin–proteasome
pathway.
In Vivo Phenotype
We performed standard histologic analyses of kidneys from
Actn4
K228/K228E mice, as well as Actn4
K228/þ and wild-type
littermates. In Actn4
K228/K228E mice as old as 13 mo, we saw no
abnormalities by light microscopy with periodic acid–Schiff
(PAS) and hematoxylin-and-eosin (H & E) staining. All of the
11 Actn4
K228/K228E kidneys examined by electron microscopy
had abnormalities in podocyte structure. Typically, these
consisted of focal areas of foot process effacement (Figure
5A). By contrast, we found mild abnormalities in one of 13
wild-type and one of nine Actn4
K228E/þ littermates. Mice were
typically genotyped at or shortly before the time of weaning
(at approximately 3 wk of age). Only 10% (23 of 231) of the
offspring of crosses between heterozygous mice were homo-
zygous for the K228E change, suggesting increased peri- or
neonatal lethality in the homozygous mice, similar to what we
have observed in Actn4 null mice (Kos et al. 2003). In
Actn4
K228/K228E mice, we frequently observed the appearance
of abnormal electron-dense structures in the podocyte cell
bodies (Figure 5D).
Figure 2. Mutant a-Actinin-4 Behavior in
Cells
(A) Mutant and wild-type a-actinin-4
show different localization and dynamics
when expressed in a conditionally im-
mortalized differentiated mouse podo-
cyte cell line. Differentiated podocytes
were injected in the nucleus with equal
concentrations of expression plasmid for
GFP fusions of mutant and wild-type
actinins. At 2–4 h after injections, cells
were imaged and both phase and ﬂuo-
rescence images recorded as described in
the Materials and Methods. To illustrate
changes in distribution of the ﬂuores-
cence signal, three ﬂuorescence images
each 1 min apart were overlaid as red,
green, and blue panes. Areas of ﬂuores-
cence that were the same in all panes
show as white, while dynamic areas are
indicated by the color. The top panel
indicates the initial phase and overlain
dynamic ﬂuorescence images of wild-
type a-actinin-4, while the bottom two
panels illustrate characteristic results for
mutants K228E and T232I at 3 min time
intervals. (See Videos S1–S3.)
(B) Transfections in podocytes derived
from mutant and wild-type mice. When
transfected into conditionally immortal-
ized podocytes of all three a-actinin-4
genotypes (þ/þ, K228E/þ, or K228E/
K228E), wild-type GFP–a-actinin-4 shows
diffuse cytoskeletal localization. Mutant
GFP–a-actinin-4 shows a similar alter-
ation in localization when expressed in
these three cells types.
DOI: 10.1371/journal.pbio.0020167.g002
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a-Actinin-4 Mutations in Kidney DiseaseWe measured urine protein excretion in mice of ﬁve
different genotypes: wild-type (Actn4
þ/þ), heterozyogtes for
either a null or K228E allele (Actn4
þ/– and Actn4
K228E/þ), and
homozoygotes for either a null or K228E allele (Actn4
–/– and
Actn4
K228E/K228E). Results were quite variable within each
genotypic group of mice (likely reﬂecting differences in age
and genetic background). However, the overall pattern of
protein excretion was similar in the Actn4
þ/þ, Actn4
þ/–, and
Actn4
K228E/þ mice, while both groups of homozygous mutant
mice (Actn4
–/– and Actn4
K228E/K228E) had signiﬁcantly greater—
and similar—degrees of proteinuria (Figure 6B). We did not
see signiﬁcant differences in serum creatinine levels or blood
urea nitrogen levels (BUN) between mice of the three
genotypes (Figure 6A), nor did we identify any single mutant
mouse with signiﬁcant BUN or creatinine elevations.
To determine whether the K228E point mutation altered
a-actinin-4 localization in vivo, we performed indirect IF
studies. As shown in Figure 6A, a-actinin-4 appears to be
mislocalized and aggregated in Actn4
K228E/K228E kidneys. By
contrast, we see no difference in the expression of slit-
diaphragm proteins ZO-1 and nephrin. The merged ZO-1/
Actn4 images show overlapping patterns of expression in the
wild-type and Actn4
K228E/þ mice, but clearly distinct expres-
sion patterns in the Actn4
K228E/K228E mice.
Figure 3. ‘‘Knockin’’ Mouse Model
(A) Targeting construct. As we have described elsewhere (Kos et al. 2003), targeting initially resulted in a ‘‘knockout’’ allele, due to disruption of
normal transcription, presumably by the intronic loxP-ﬂanked neomycin resistance cassette. After breeding to Cre transgenic mice, this
neomycin cassette was excised, as illustrated.
(B) Northern blot analysis using kidney total RNA illustrates that the expression of the Actn4 transcript in K228E/K228E is similar to the
expression in wild-type mice.
(C) RT-PCR and sequencing of the relevant portion of Actn4 exon 8 conﬁrms that the transcript in mice homozygous for the targeted allele
contains the desired point mutation (top, wild-type; bottom, targeted).
(D) Western blot showing markedly decreased expression of a-actinin-4 protein in K228E/K228E homozygous mice and moderately decreased
expression in heterozygotes. Shown are blots using protein from cultured ﬁbroblasts. Results were similar using protein extracted from lung,
brain, liver, and kidney (data not shown). b-actin control is shown below.
(E) Western blot showing expression of a-actinin-4 in lymphocytes from a human K228E/þheterozygote (Kaplan et al. 2000) and three wild-type
controls (two related, one unrelated). b-actin control is shown below.
DOI: 10.1371/journal.pbio.0020167.g003
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a-Actinin-4 Mutations in Kidney DiseaseWe examined a-actinin-4 localization in a human
ACTN4
K228E/þ kidney biopsy sample (Figure 6B). Although
we are cautious in our interpretation, given the availability of
only one biopsy sample, there appears to be a more punctate
appearance to the a-actinin-4 distribution, consistent with
the existence of some a-actinin-4 aggregates in human
heterozygotes.
Discussion
We have previously shown that dominantly inherited point
mutations in the a-actinin-4 gene ACTN4 cause a form of
human glomerular disease (Kaplan et al. 2000). We have also
shown that mice lacking a-actinin-4 expression develop a
severe glomerular lesion (Kos et al. 2003). Here we have
further explored the biochemical and cell biologic alterations
caused by disease-associated a-actinin-4 mutations.
Human a-actinin-4-associated FSGS is characterized by a
dominant pattern of inheritance. Affected individuals typi-
cally develop disease in adulthood. Some individuals develop
progressive renal failure, others develop moderate protein-
uria, while a few show no evidence of kidney dysfunction well
into adulthood. This contrasts with other recently elucidated
inherited disorders of the podocyte caused by mutations in
the slit-diaphragm proteins nephrin and podocin, where
disease typically presents in the neonatal period or in
childhood and follows a recessive pattern of inheritance
(Kestila et al. 1998; Boute et al. 2000). Mice lacking slit-
diaphragm proteins CD2AP and Neph-1 similarly present
with very early-onset nephrosis (Shih et al. 1998; Donoviel et
al. 2001). Furthermore, in contrast to the typically diffuse
podocyte foot process effacement observed in kidney biopsies
from individuals with these recessive forms of disease,
individuals with ACTN4-associated FSGS have focal podocyte
abnormalities, nonnephrotic levels of proteinuria, and slowly
progressive adult-onset disease leading to signiﬁcant (and
often end-stage) renal failure in adulthood.
These phenotypic differences themselves suggest a differ-
ent mechanism of disease from what is observed with slit-
diaphragm protein defects. Our earlier experiments sug-
gested that mutant a-actinin-4 binds actin ﬁlaments more
strongly than wild-type a-actinin-4 in vitro. However, this
may reﬂect a propensity toward oligomerization rather than
increased F-actin binding per se. The ﬁnding that the mutant
a-actinin-4 forms aggregates with greatly decreased half-life
suggests two possible models to explain the human (and
mouse) disease. One model would explain the development of
podocyte damage as a direct effect of protein aggregation
and the toxic effects of such aggregation, as is observed in
several degenerative neurologic conditions such as Alzheimer
and Parkinson diseases (Horwich 2002). The second model
explains the disease as a loss-of-function disease, reﬂecting
the increased rate of mutant a-actinin-4 degradation.
We do not regard these models as mutually exclusive. In
fact, we believe it likely that the development of disease may
involve both of these mechanisms. It is interesting to note
that a-actinin-4-mediated kidney disease bears some similar-
ities to the adult-onset neurodegenerative condition Hun-
tington disease. In Huntington disease, dominant mutations
that lead to expanded polyglutamine tracts cause neuro-
degeneration. The mutant huntingtin protein is misfolded
and forms aggregates that are thought to have dominant,
toxic effects on neuron function (Bucciantini et al. 2002;
Bates 2003). These proteins also play critical and non-
redundant roles in the relevant organs: analogous to what
we have observed in a-actinin-4-deﬁcient mice, mice with
reduced huntingtin expression show abnormal brain develop-
ment and perinatal lethality (White et al. 1997).
In contrast to humans, mice heterozygous for a-actinin-4
mutations do not have overt disease. We suspect that in
humans, over a timespan of several decades, the combination
of decreased a-actinin-4 expression and the formation of
aggregates ultimately proves toxic. We suggest that the
relatively short life of mice compared with that of humans
may be the major explanation of this difference. Not all
humans carrying disease-associated mutations develop clin-
ical disease (Kaplan et al. 2000). Disease, in both human and
murine heterozygotes, likely requires a ‘‘second hit,’’ either in
Figure 4. a-Actinin-4 Synthesis and Deg-
radation
(A and B) Synthesis of a-actinin-4 by
wild-type and K228E/K228E ﬁbroblasts.
The rate of increase in the accumulation
of mutant and wild-type a-actinin-4 is
similar, as indicated by the superim-
posed shapes of the synthesis curves.
(C and D) Pulse–chase experiments
showing degradation of a-actinin-4 in
K228E/K228E cells. Half-life of wild-type
a-actinin-4 is greater than 30 h. Half-life
of mutant a-actinin-4 is approximately
15 h.
(E) Half-life of K228E mutant a-actinin-4
is restored to near-normal levels by the
addition of lactacystin. Shown is labeled
a-actinin-4 levels, expressed as a per-
centage of a-actinin-4 at time 0 and at 16
h and in the presence of 2.5 lM
lactacystin in DMSO or in DMSO alone.
DOI: 10.1371/journal.pbio.0020167.g004
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a-Actinin-4 Mutations in Kidney Diseasethe strict genetic sense of a second mutation in the relevant
cell type or a ‘‘physiologic hit,’’ such as elevated blood
pressure, renal toxin exposure, or vascular disease, to name
three examples. We suspect that renal stresses will uncover
deleterious renal phenotypes in heterozygous mice, similar to
the disease observed in humans. With aging and gradual
accumulation of aggregates in the terminally differentiated
podocyte, we believe that humans with ACTN4 mutations
become increasingly susceptible to minor insults. We note
also that mice, unlike humans, express a-actinin-1 in
podocytes (Kos et al. 2003). This may help stabilize mutant
a-actinin-4 or may produce more redundancy, giving the
mouse glomerulus greater protection to perturbations in this
pathway.
We note that, as shown in Figure 7, the appearance of a-
actinin-4 is more punctate in the kidney from a K228E
heterozygous individual than a control, consistent with the
existence of aggregates in heterozygous humans. This effect,
however, is subtle, and is consistent with the lack of any
detectable renal phenotype in several humans who carry
disease-associated ACTN4 mutations (Kaplan et al. 2000).
Although the number of ACTN4 mutations we have found is
small, we have not detected any human disease-associated
ACTN4 mutations to date that lead to premature termination,
suggesting that simple haploinsufﬁciency may not by itself
cause disease (our unpublished data).
As indicated in Figure 5 and in the text, heterozygous
K228E Actn4 knockin mice have no clear phenotype either by
histologic analysis at the light and electron microscopic levels
or by analysis of urine protein and serum creatinine. Even at
more advanced ages, the Actn4
K228E/þ mice appear normal. By
contrast, we observe clear glomerular phenotypes in both
Actn4
–/– and Actn4
K228E/K228E mice. Our genetic observations
are consistent with our biochemical observations. Speciﬁ-
cally, we believe that a-actinin-4 mutations lead to a
reduction in normal a-actinin-4 activity and to protein
aggregation and that glomerular phenotypes reﬂect both loss
of normal a-actinin-4 function and toxic effects of aggregated
a-actinin-4. While the disease observed in homozygous
Actn4
K228E/K228E mice may primarily reﬂect loss of function
resulting from rapid a-actinin-4 degradation, heterozygous
Figure 5. In Vivo Phenotype
Electron micrographs from Actn4 wild-type (A) and Actn4
K228E/K228E
mice (B–D). As shown, Actn4
K228E/K228E mice were found to have
abnormalities that were typically focal, with some areas of podocyte
foot process effacement (B), as well as areas that appeared essentially
normal (C). Bottom image ([D] using tannic acid counterstaining)
illustrates electron-dense deposits observed in several podocyte cell
bodies in Actn4
K228E/K228E mice. No such deposits were observed in
wild-type or heterozygous mice.
DOI: 10.1371/journal.pbio.0020167.g005
Figure 6. Biochemical Characteristics of
Mutant Mice
(A) Average BUN and creatinine levels in
Actn4
K228E/– (n = 12), Actn4
þ/þ (n = 8),
and Actn4
K228E/K228E (n = 12) mice at the
time of sacriﬁce. Differences were not
statistically signiﬁcant. Error bars show
standard deviation.
(B) Summary of proteinuria in wild-type,
Actn4
þ/–, Actn4
K228E/–, Actn4
–/–,a n d
Actn4
K228E/K228E mice, measured by albu-
min dipstick. Distribution of measure-
ments are illustrated graphically for each
genotype.
DOI: 10.1371/journal.pbio.0020167.g006
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a-Actinin-4 Mutations in Kidney Diseasehumans may show slow development of podocyte damage
from the effects of a-actinin-4 aggregation.
Is alteration of a-actinin-4 expression or conformation a
cause or a mediator of secondary forms of kidney disease?
These seem plausible hypotheses given the data presented
here, together with results from other investigators showing
alterations in a-actinin-4 levels in association with protein-
uria in certain animal models (Shirato et al. 1996; Smoyer et
al. 1997). This suggests that physiologic processes that alter
the expression, conformation, or both of this (and other)
cytoskeletal proteins, either at the protein or the transcript
level, might be amenable to interventions that restore normal
patterns of protein expression.
Materials and Methods
Cell and cell culture. Mouse podocytes were kindly provided by Dr.
Peter Mundel (Albert Einstein College of Medicine, Bronx, New York,
United States) and cultured as described previously (Mundel et al.
1997). In brief, undifferentiated podocytes were cultured in RPMI-
1640 (Cellgro, CellGenix, Freiburg, Germany) medium containing
10% fetal calf serum (FCS) and 20 U/ml c-interferon (c-IFN) at 338C
and 5% CO2. Differentiated podocytes were cultured in the medium
containing no c-IFN at 378C. Additional conditionally immortalized
podocytes from ‘‘knockin’’ litters were generated exactly as described
previously (Mundel et al. 1997). Fibroblasts were derived from lungs
dissected from newly sacriﬁced adult mouse littermates of different
genotypes. Cells were propagated in culture and immortalized by
transfection with an SV-40 large T-antigen expression plasmid using
Fugene 6 transfection reagent (Roche, Basel, Switzerland).
Protein extraction. Fibroblasts were allowed to grow to conﬂuence,
then scraped off the tissue culture plate in the presence of cold
phosphate-buffered saline (PBS) and spun at 3,000 rpm at 48C for 10
min. Lymphocytes were isolated from whole blood with Histopaque-
1077 solution (Sigma, St. Louis, Missouri, United States) following the
manufacturer’s instructions. The pellets were resuspended in ice-cold
lysis buffer (150 mM NaCl, 50 mM Tris [pH 8.0], 1% Triton X-100, 1
mM Na-orthovanadate, 4 lM microcystin, and protease inhibitor). We
collected the supernatant and estimated the protein concentration
using either the Bradford method or equalizing the protein
concentration in different lysates by Western blot using b-actin as a
standard.
Transient transfection and Immunocytochemistry. We mutated a
wild-type pBluescript-GFP-ACTN4 clone using a QuickChange kit
(Stratagene, La Jolla, California, United States) to create clones
harboring each of three disease-associated mutations (K228E, T232I,
S235P) (Kaplan et al. 2000). These mutant and wild-type a-actinin-4
clones were transfected into podocytes using Fugene 6 (Roche). Cells
60 h after transfection were ﬁxed in 2% paraformaldehyde and 4%
sucrose in PBS for 5 min and then permeabilized in 0.3% Triton for 5
min. Fixed cells were blocked with 2% FCS, 2% BSA, 0.2% ﬁsh gelatin
in PBS for 60 min and incubated with anti-a-actinin-4 antibody, and
rabbit antigen–antibody complexes were visualized with ﬂuoro-
chrome-conjugated secondary antibodies.
Sucrose gradient studies. Sucrose gradients of 5%–20% and 10%–
40% were made using a buffer containing 0.02 M Tris–HCl (pH 7.5),
0.15M NaCl, 0.1 mM EDTA, and 0.2 mM of DTT and were internally
calibrated with BSA, carbonic anhydrase, and catalase. In vitro
translated and radiolabeled wild-type and mutant a-actinin-4 (K228E,
T232I, S235P) were loaded onto the gradient, centrifuged at 40,000
rpm for 15 h at 48C, and eluted into 0.2 ml fractions. Eluates were
analyzed by SDS-PAGE and autoradiography.
Pulse–chase studies. Immortalized mouse ﬁbroblasts were incu-
bated in methionine-free MEM medium containing 10% FCS
(dialyzed overnight using 12K-14K SPECTRA/POR porous membrane
in normal saline at 48C) and 25 mM HEPES for 20 min at 378C.
[
35S]Methionine was added to a ﬁnal concentration of 0.1 mCi to
pulse the cells. Cells were pulse labeled for 0, 15, 30, 60, 120, 180, and
240 min. To study the degradation of a-actinin-4, cells were pulsed
for 3 h and then chased for 0, 3, 6, 12, 20, 24, and 30 h with excess cold
methionine. We used anti-a-actinin-4 antibody recognizing the
N-terminus to precipitate a-actinin-4 from the cell lysates. Protein
A–sepharose beads (Pierce Biotechnology, Rockford, Illinois, United
States) were preincubated with the anti-a-actinin-4 antibody for 2 h
at 48C and then incubated with the lysates overnight at 48C. The beads
were washed with lysis buffer and resuspended in SDS-PAGE loading
buffer. Samples were resolved on a 10% polyacrylamide gel and
visualized by exposure to radiographic ﬁlm. For lactacystin treat-
ment, cells were ﬁrst pulsed for 3 h as above, followed by addition of
2.5 lM lactacystin dissolved in DMSO (A. G. Scientiﬁc, San Diego,
California, United States) or 0.125% DMSO alone with cold
methionine.
Nuclear DNA injection and imaging. For injection and imaging,
cells were cultured on MatTek Corporation (Ashland, Massachusetts,
United States) 35 mm coverslip dishes in F12 media (BioFluids,
BioSource International, Carmarillo, California, United States) with-
o u tp h e n o lr e da n ds u p p l e m e n t e dw i t h1 0m MH E P E Sa n d
antibiotics. Plasmid DNA at 0.5–2.0 ng/nl was injected in cell nuclei
using a Narishige (Lake Forest, California, United States) IM-200
picoliter pressure injection system. OD microcapillary glass pipettes
Figure 7. In Situ Protein Localization
(A) IF studies of glomerular protein
expression in Actn4
þ/þ, Actn4
K228E/þ , and
Actn4
K228E/K228E mice. As indicated, ex-
pression of a-actinin-4, ZO-1, and neph-
rin is shown, as is a merged image of a-
actinin-4 and ZO-1 expression.
(B) Glomerular expression of a-actinin-4
in normal human kidney and in an
individual heterozygous for a K228E
mutation.
DOI: 10.1371/journal.pbio.0020167.g007
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a-Actinin-4 Mutations in Kidney Disease(1.0 mm) were pulled to a ﬁne tip using a Narishige PB-7 needle
puller. Cells were maintained at 378C using a modiﬁed Harvard
Apparatus (Hopkinton, Massachusetts, United States) microscope
incubator mounted on a Nikon (Tokyo, Japan) Diaphot 300 inverted
microscope. Images were collected using a Princeton Instruments
MicroMax 1300Y cooled CCD camera (Roper Scientiﬁc, Tucson,
Arizona, United States). Excitation and emission wavelengths were
controlled using dichroic and bandbass ﬁlters from Omega Optical
(Brattleboro, Vermont, United States) and a Sutter Instrument
(Novato, California, United States) Lambda 10–2 ﬁlter wheel image
acquisition. Device control and postacquisition processing were done
with Isee Imaging Software (Inovision Corporation Raleigh, North
Carolina, United States).
Actinin dynamics display. To display the changes in GFP–actinin
distribution over time, images collected at 1 min intervals were used
sequentially as red, green, and blue channels of a RGB composite
image. Areas of signal that did not change have equal representation
in each of the channels and generate a white signal in the ﬁnal image.
Areas of signal that did change on a minute-to-minute basis are
indicated by either a red, green, or blue hue. For example, a region
rich in red would indicate an signal present in the ﬁrst image, but
absent in the two sequential images, indicative of a withdraw or loss
of signal in that region.
Generation of K228E mutant mice. Previously, we described the
development of a mouse model lacking detectable Actn4 expression
(Kos et al. 2003). These mice harbor a germline mutation in exon 8 of
Actn4 encoding a K228E substitution, as well as an intronic loxP-
ﬂanked neomycin resistance cassette. We bred these mice to
transgenic mice with germline expression of Cre recombinase (129-
TgN(Prm-Cre)58Og; Jackson Laboratory, Bar Harbor, Maine, United
States). We veriﬁed excision of the neomycin resistance cassette by
PCR. Heterozygous mice were crossed to obtain mice homozygous for
the K228E substitution. Mice were genotyped for the K228E as
described previously (Kos et al. 2003). We used Trizol reagent to
extract RNA from kidneys for RT-PCR and for Northern blot
analysis.
Mouse phenotyping. Freshly harvested kidneys were ﬁxed in
Bouin’s solution. H & E and PAS staining were performed using
standard methodology. Electron microscopy was performed after
ﬁxation in Karnovsky’s media using standard diagnostic protocols.
For the electron micrographs, all of the glomeruli imaged were from
as deep into the renal cortex as possible. Indirect IF studies were
performed using standard methods (Kos et al. 2003). Urine micro-
albumin was assessed by a reader blinded to mouse genotype using
albumin dipsticks (Albustix, Bayer, Leverkusen, Germany). BUN and
creatinine measurements were performed at the clinical chemistry
laboratory at Brigham and Women’s Hospital.
Supporting Information
Video S1. Podocytes Following Nuclear Injection of Wild-Type GFP-
a-Actinin-4 cDNA
Found at DOI: 10.1371/journal.pbio.0020167.sv001 (14.8 MB MOV).
Video S2. Podocytes Following Nuclear Injection of K228E GFP-a-
Actinin-4 cDNA
Found at DOI: 10.1371/journal.pbio.0020167.sv002 (11.8 MB MOV).
Video S3. Podocytes Following Nuclear Injection of T232I GFP-a-
Actinin-4 cDNA
Found at DOI: 10.1371/journal.pbio.0020167.sv003 (10.9 MB MOV).
Accession Numbers
GenBank accession numbers for genes and proteins discussed in this
paper are NM_004924 and NP_004915 (human ACTN4;a l s o
LocusLink ID 81) and NM_021895 and NP_068695 (mouse Actn4;
also LocusLink ID 60595). OMIM numbers are 603278 (FSGS-1) and
604638 (ACTN4).
Acknowledgments
These experiments were supported by National Institutes of Health
grants DK59588 (to MRP), GM55223 (to BMD), and GM057256 (to
PGA). We thank Larry Holzman and Peter Mundel for gifts of anti-
synaptopodin and anti-nephrin antibodies and Dr. Mundel for the
podocyte cell line. We thank Kazufumi Honda and Carol Otey for the
GFP–a-actinin-4 clone.
Conﬂicts of interest. The authors have declared that no conﬂicts of
interest exist.
Author contributions. JY, PGA, BMD, and MRP conceived and
designed the experiments. JY, TCL, CHK, JMH, and PGA performed
the experiments. JY, JMH, PGA, BMD, and MRP analyzed the data. JH,
PGA, and MRP contributed reagents/materials/analysis tools. JY and
MRP wrote the paper. &
References
Bates G (2003) Huntingtin aggregation and toxicity in Huntington’s disease.
Lancet 361: 1642–1644.
Boute N, Gribouval O, Roselli S, Benessy F, Lee H, et al. (2000) NPHS2,
encoding the glomerular protein podocin, is mutated in autosomal recessive
steroid-resistant nephrotic syndrome. Nat Genet 24: 349–354.
Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, et al. (2002) Inherent
toxicity of aggregates implies a common mechanism for protein misfolding
diseases. Nature 416: 507–511.
Chan Y, Tong HQ, Beggs AH, Kunkel LM (1998) Human skeletal muscle-
speciﬁc alpha-actinin-2 and -3 isoforms form homodimers and hetero-
dimers in vitro and in vivo. Biochem Biophys Res Commun 248: 134–139.
Donoviel DB, Freed DD, Vogel H, Potter DG, Hawkins E, et al. (2001)
Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein
with homology to NEPHRIN. Mol Cell Biol 21: 4829–4836.
Feramisco JR, Burridge K (1980) A rapid puriﬁcation of alpha-actinin, ﬁlamin,
and a 130,000-dalton protein from smooth muscle. J Biol Chem 255: 1194–
1199.
Honda K, Yamada T, Endo R, Ino Y, Gotoh M, et al. (1998) Actinin-4, a novel
actin-bundling protein associated with cell motility and cancer invasion. J
Cell Biol 140: 1383–1393.
Horwich A (2002) Protein aggregation in disease: A role for folding
intermediates forming speciﬁc multimeric interactions. J Clin Invest 110:
1221–1232.
Ichikawa I, Fogo A (1996) Focal segmental glomerulosclerosis. Pediatr Nephrol
10: 374–391.
Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, et al. (2000) Mutations
in ACTN4, encoding alpha-actinin-4, cause familial focal segmental
glomerulosclerosis. Nat Genet 24: 251–256.
Kestila M, Lenkkeri U, Mannikko M, Lamerdin J, McCready P, et al. (1998)
Positionally cloned gene for a novel glomerular protein—nephrin—is
mutated in congenital nephrotic syndrome. Mol Cell 1: 575–582.
Kos CH, Le TC, Sinha S, Henderson JM, Kim SH, et al. (2003) Mice deﬁcient in
alpha-actinin-4 have severe glomerular disease. J Clin Invest 111: 1683–1690.
Michaud JL, Lemieux LI, Dube M, Vanderhyden BC, Robertson SJ, et al.
(2003) Focal and segmental glomerulosclerosis in mice with podocyte-
speciﬁc expression of mutant alpha-actinin-4. J Am Soc Nephrol 14: 1200–
1211.
Mundel P, Heid HW, Mundel TM, Kruger M, Reiser J, et al. (1997)
Synaptopodin: An actin-associated protein in telencephalic dendrites and
renal podocytes. J Cell Biol 139: 193–204.
Shih NY, Li J, Karpitskii V, Nguyen A, Dustin ML, et al. (1999) Congenital
nephrotic syndrome in mice lacking CD2-associated protein. Science 286:
312–315.
Shirato I, Sakai T, Kimura K, Tomino Y, Kriz W (1996) Cytoskeletal changes in
podocytes associated with foot process effacement in Masugi nephritis. Am J
Pathol 148: 1283–1296.
Smoyer WE, Mundel P, Gupta A, Welsh MJ (1997) Podocyte alpha-actinin
induction precedes foot process effacement in experimental nephrotic
syndrome. Am J Physiol 273: F150–F157.
Somlo S, Mundel P (2000) Getting a foothold in nephrotic syndrome. Nat Genet
24: 333–335.
Takada F, Beggs AH (2002) Alpha-actinins. In: Creighton TE, editor.
Encyclopedia of molecular medicine. New York: John Wiley. pp. 122–127.
White JK, Auerbach W, Duyao MP, Vonsattel JP, Gusella JF, et al. (1997)
Huntingtin is required for neurogenesis and is not impaired by the
Huntington’s disease CAG expansion. Nat Genet 17: 404–410.
PLoS Biology | http://biology.plosjournals.org June 2004 | Volume 2 | Issue 6 | Page 0794
a-Actinin-4 Mutations in Kidney Disease